OncoMatch/Clinical Trials/NCT06259552
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Is NCT06259552 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SPX- 303 for solid tumor.
Treatment: SPX- 303 — Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any prior therapy
Patients who have progressed on or after prior therapy and who are not eligible for available treatment options
Cannot have received: immunotherapy (IO) discontinued due to irAE
History of permanent discontinuation of prior IO therapy due to irAE
Cannot have received: ILT2 and/or ILT4 inhibitor or HLA G targeting agent
Prior treatment targeting ILT2 and/or ILT4 or targeting HLA G
Lab requirements
Blood counts
ANC ≥1 x 10^9/L; platelets ≥75 x 10^9/L; hemoglobin ≥9 g/dL
Kidney function
creatinine clearance (CrCl) ≥ 30 mL/min
Liver function
bilirubin ≤1.5x ULN (except Gilbert syndrome: ≤3x ULN), AST and ALT ≤2.5x ULN (≤5x ULN if liver metastases present)
Cardiac function
LVEF ≥ 45% by MUGA or ECHO; QTcF ≤480 msec
Adequate hepatic function; bilirubin ≤1.5x ULN (except for patients with Gilbert syndrome: ≤ 3xULN), AST, and ALT ≤2.5 x ULN (≤5 x ULN if liver metastases present). Adequate renal function as calculated (e.g. Cockroft Gault) creatine clearance (CrCl) ≥ 30 mL/min or 24-hour urine CrCl ≥ 30 mL/min. Adequate hematological function: ANC ≥1 x 10^9/L; platelets ≥75 x 10^9/L, hemoglobin ≥9 g/dL. Adequate cardiac function: LVEF ≥ 45% by MUGA or ECHO scan. Fridericia-corrected QT interval (QTcF) ≤480 msec.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Phoenix, Arizona
- HonorHealth Research and Innovation Institute · Scottsdale, Arizona
- Mayo Clinic Florida · Jacksonville, Florida
- Mayo Clinic Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify